We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$580M
Turnover
39.22%
1-Year Est. Return
29.81%
This Fund
S&P 500
This Quarter
Est. Return
-17.49%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$214M
AUM Growth
-$13.8M
(-6.1%)
Cap. Flow
+$50.8M
Cap. Flow
% of AUM
23.74%
Top 10 Holdings %
Top 10 Hldgs %
55.85%
Holding
56
New
18
Increased
15
Reduced
11
Closed
12
Avg Time Held Equity + Options
0.6
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.7
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$13.7M |
| 2 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$7.82M |
| 3 |
Cue Biopharma
CUE
|
+$6.7M |
| 4 |
Direxion Daily Small Cap Bear 3x ETF
TZA
|
+$6.06M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$5.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ARQL
Arqule Inc
ARQL
|
+$8.99M |
| 2 |
United Therapeutics
UTHR
|
+$6.39M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$6.02M |
| 4 |
Zimmer Biomet
ZBH
|
+$3.38M |
| 5 |
Envista
NVST
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.8% |
| 2 | Miscellaneous | 4.08% |
| 3 | Technology | 2.61% |
| 4 | Energy | 2.29% |
| 5 | Industrials | 0.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
PRTK
51
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| – | – |
-450,000
| Closed | -$1.81M | – |
|
52
DELISTED
Molecular Templates, Inc.
MTEM
| – | – |
-10,726
| Closed | -$2.25M | – |
|
|
ARNA
53
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
| – | – |
-142,400
| Closed | -$6.47M | – |
|
|
TLGT
54
DELISTED
Teligent, Inc
TLGT
| – | – |
-148,453
| Closed | -$632K | – |
|
|
SBBP
55
DELISTED
Strongbridge Biopharma plc.
SBBP
| – | – |
-1,258,224
| Closed | -$2.63M | – |
|
|
ARQL
56
DELISTED
Arqule Inc
ARQL
| – | – |
-450,326
| Closed | -$8.99M | – |
|
Similar funds
SC
CCWM
RIS
MFS
GFI
PWM
CA
SSP
Prosight Management's Q1 2020 Portfolio in Review
As of Q1 2020, Prosight Management held 56 positions worth $214M, down 6.1% from $228M the previous quarter. Its ten largest holdings account for 56% of the portfolio.
Prosight Management deployed $50.8M of net new capital in Q1 2020, opening 18 new positions and adding to 15 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Technology.
On the sell side, the largest reduction was United Therapeutics, an estimated $6.39M trimmed.
- Prosight Management's largest Q1 2020 buy was Alexion Pharmaceuticals: 140,000 shares worth $12.6M.
- Prosight Management added most to Cue Biopharma in Q1 2020, an estimated $6.7M increase.
- Prosight Management's biggest Q1 2020 reduction was United Therapeutics, cutting an estimated $6.39M.
- Prosight Management fully exited Arqule Inc in Q1 2020, selling an estimated $8.99M.
- Prosight Management's ten largest holdings make up 56% of its $214M portfolio in Q1 2020.
- Prosight Management opened 18 new positions and closed 12 in Q1 2020.
- Prosight Management's portfolio value fell 6.1% quarter-over-quarter to $214M.
Based on Prosight Management's 13F filing for Q1 2020, filed 15 May 2020.